Geode Capital Management LLC Raises Stake in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)

Geode Capital Management LLC increased its stake in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) by 259.8% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 238,737 shares of the company’s stock after acquiring an additional 172,382 shares during the quarter. Geode Capital Management LLC’s holdings in Telomir Pharmaceuticals were worth $1,533,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new position in shares of Telomir Pharmaceuticals during the second quarter worth approximately $241,000. Beaird Harris Wealth Management LLC boosted its holdings in shares of Telomir Pharmaceuticals by 212.9% in the second quarter. Beaird Harris Wealth Management LLC now owns 14,623 shares of the company’s stock valued at $70,000 after purchasing an additional 9,950 shares during the period. Suncoast Equity Management grew its stake in Telomir Pharmaceuticals by 109.9% in the third quarter. Suncoast Equity Management now owns 51,194 shares of the company’s stock worth $329,000 after purchasing an additional 26,803 shares in the last quarter. State Street Corp increased its holdings in Telomir Pharmaceuticals by 99.1% during the 3rd quarter. State Street Corp now owns 36,094 shares of the company’s stock worth $232,000 after purchasing an additional 17,967 shares during the period. Finally, Barclays PLC raised its position in Telomir Pharmaceuticals by 325.1% during the 3rd quarter. Barclays PLC now owns 7,018 shares of the company’s stock valued at $45,000 after purchasing an additional 5,367 shares in the last quarter.

Telomir Pharmaceuticals Trading Down 5.5 %

Shares of TELO stock opened at $4.30 on Thursday. Telomir Pharmaceuticals, Inc. has a twelve month low of $3.11 and a twelve month high of $20.72. The stock has a fifty day simple moving average of $4.57 and a two-hundred day simple moving average of $4.76.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals, Inc, a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems.